Notice of Class Action Lawsuit Against Atara Biotherapeutics Securities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 43 minutes ago
0mins
Should l Buy ATRA?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action, as those who do not will not be eligible for compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true information was revealed, negatively impacting the company's financial condition.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked first in 2017 for the number of settlements, showcasing its expertise and success in this field.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.760
Low
18.00
Averages
21.50
High
25.00
Current: 4.760
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice of Class Action Lawsuit Against Atara Biotherapeutics Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action, as those who do not will not be eligible for compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true information was revealed, negatively impacting the company's financial condition.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked first in 2017 for the number of settlements, showcasing its expertise and success in this field.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Investor Class Action Lawsuit Reminder
- Lufax Lawsuit Details: Lufax Holding Ltd. (NYSE:LU) is facing a class action lawsuit for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026, which could adversely affect the company's reputation and stock price.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is being sued for undisclosed manufacturing issues and clinical trial risks during the class period from May 20, 2024, to January 9, 2026, requiring lead plaintiff motions by May 22, 2026, potentially jeopardizing future FDA approvals and impacting the company's financial outlook.
- Coty Lawsuit Overview: Coty Inc. (NYSE:COTY) faces a class action lawsuit for underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026, which may lead to significant financial repercussions for the company.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to contact them for legal advice to protect their rights and mitigate potential financial losses.
See More
Faruqi & Faruqi Investigates Atara Biotherapeutics for Securities Claims
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating Atara Biotherapeutics for potential claims related to securities purchased between May 20, 2024, and January 9, 2026, indicating risks of investor losses.
- Investor Rights Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Encouragement: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly for legal consultation and support, demonstrating a commitment to client advocacy.
- Potential Legal Consequences: This investigation could lead to legal action against Atara, which, if successful, may negatively impact the company's reputation and stock price, prompting investors to closely monitor developments.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026.
- Allegation Details: The lawsuit alleges that Atara issued false and misleading statements regarding its business and operations, particularly concerning manufacturing issues and deficiencies in the ALLELE study that jeopardized the FDA approval of the tabelecleucel Biologics License Application.
- Potential Impact: The identified manufacturing issues expose Atara to increased regulatory scrutiny and threaten ongoing clinical trials, which could significantly harm the company's financial condition and operational viability.
- Investor Rights: Investors must apply by May 22, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations to affected parties.
See More
Reminder of Atara Biotherapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true situation emerged, negatively impacting the company's financial condition and market confidence.
- Choosing Legal Counsel: The Rosen Law Firm emphasizes the importance of selecting experienced legal counsel, noting that many firms issuing notices lack the capability to handle securities class actions, urging investors to be cautious in their legal representation choices.
- Historical Achievements: The Rosen Law Firm has recovered over $438 million for investors in 2019 alone and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and influence in the securities class action field.
See More
Atara Biotherapeutics Faces Class Action for Securities Fraud
- Lawsuit Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 20, 2024, and January 9, 2026, with a deadline to contact the firm by May 22, 2026, to participate.
- False Statements: The complaint alleges that Atara made misleading statements regarding its ALLELE study, which suffered from manufacturing issues, making FDA approval for its tabelecleucel BLA unlikely, thus misleading investors about the product's prospects.
- Increased Regulatory Risk: Atara's manufacturing deficiencies have heightened the risk of regulatory actions, which not only tarnishes the company's market reputation but also poses potential future financial losses, leading to investor damages once the truth emerged.
- Legal Consultation Opportunity: The Schall Law Firm offers legal consultations for affected shareholders, encouraging them to take action before class certification to protect their rights and seek compensation for their losses.
See More
Notice of Class Action Lawsuit Against Atara Biotherapeutics Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action, as those who do not will not be eligible for compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true information was revealed, negatively impacting the company's financial condition.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked first in 2017 for the number of settlements, showcasing its expertise and success in this field.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Investor Class Action Lawsuit Reminder
- Lufax Lawsuit Details: Lufax Holding Ltd. (NYSE:LU) is facing a class action lawsuit for failing to disclose inadequate internal controls and misstated financial results during the period from April 7, 2023, to January 26, 2025, with a lead plaintiff deadline of May 20, 2026, which could adversely affect the company's reputation and stock price.
- Atara Biotherapeutics Lawsuit: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) is being sued for undisclosed manufacturing issues and clinical trial risks during the class period from May 20, 2024, to January 9, 2026, requiring lead plaintiff motions by May 22, 2026, potentially jeopardizing future FDA approvals and impacting the company's financial outlook.
- Coty Lawsuit Overview: Coty Inc. (NYSE:COTY) faces a class action lawsuit for underperformance in its Consumer Beauty segment and slowing market growth from November 5, 2025, to February 4, 2026, with a lead plaintiff deadline of May 22, 2026, which may lead to significant financial repercussions for the company.
- Legal Consultation Reminder: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to contact them for legal advice to protect their rights and mitigate potential financial losses.
See More
Faruqi & Faruqi Investigates Atara Biotherapeutics for Securities Claims
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating Atara Biotherapeutics for potential claims related to securities purchased between May 20, 2024, and January 9, 2026, indicating risks of investor losses.
- Investor Rights Reminder: The firm reminds investors that May 22, 2026, is the deadline to seek lead plaintiff status in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Encouragement: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly for legal consultation and support, demonstrating a commitment to client advocacy.
- Potential Legal Consequences: This investigation could lead to legal action against Atara, which, if successful, may negatively impact the company's reputation and stock price, prompting investors to closely monitor developments.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026.
- Allegation Details: The lawsuit alleges that Atara issued false and misleading statements regarding its business and operations, particularly concerning manufacturing issues and deficiencies in the ALLELE study that jeopardized the FDA approval of the tabelecleucel Biologics License Application.
- Potential Impact: The identified manufacturing issues expose Atara to increased regulatory scrutiny and threaten ongoing clinical trials, which could significantly harm the company's financial condition and operational viability.
- Investor Rights: Investors must apply by May 22, 2026, to be appointed as lead plaintiffs in the lawsuit to protect their legal rights, with Bragar Eagel & Squire offering free consultations to affected parties.
See More
Reminder of Atara Biotherapeutics Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, that they must apply to be lead plaintiff by May 22, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true situation emerged, negatively impacting the company's financial condition and market confidence.
- Choosing Legal Counsel: The Rosen Law Firm emphasizes the importance of selecting experienced legal counsel, noting that many firms issuing notices lack the capability to handle securities class actions, urging investors to be cautious in their legal representation choices.
- Historical Achievements: The Rosen Law Firm has recovered over $438 million for investors in 2019 alone and was ranked No. 1 by ISS Securities Class Action Services in 2017, showcasing its strong capabilities and influence in the securities class action field.
See More
Atara Biotherapeutics Faces Class Action for Securities Fraud
- Lawsuit Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 20, 2024, and January 9, 2026, with a deadline to contact the firm by May 22, 2026, to participate.
- False Statements: The complaint alleges that Atara made misleading statements regarding its ALLELE study, which suffered from manufacturing issues, making FDA approval for its tabelecleucel BLA unlikely, thus misleading investors about the product's prospects.
- Increased Regulatory Risk: Atara's manufacturing deficiencies have heightened the risk of regulatory actions, which not only tarnishes the company's market reputation but also poses potential future financial losses, leading to investor damages once the truth emerged.
- Legal Consultation Opportunity: The Schall Law Firm offers legal consultations for affected shareholders, encouraging them to take action before class certification to protect their rights and seek compensation for their losses.
See More
